ORIC News & Events

ORIC Pharmaceuticals announced operational highlights for 2025 and anticipated upcoming milestones. Key highlights includes: Announced rinzimetostat Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors; Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose; Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study; Expect to report multiple clinical data readouts for rinzimetostat and enozertinib in 2026, ahead of potential initiation of multiple registrational trials

ORIC Pharmaceuticals announced data from a Phase 1b trial of enozertinib, ORC-114, at the ESMO Asia Congress 2025. Data in treatment-naive and in previously treated NSCLC patients with EGFR exon 20 mutations were presented at an oral session. Key highlights: Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR , including in patients with active brain metastases; 45% ORR in 2L patients exceeds competitor benchmarks; Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate; Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial